Skip to main content

Table 1 Patient’s characteristics

From: Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma

PatientSexAge at diagnosisClinical subtypep53 activityFirst line treatmentInterval between induction therapy and As2O3 consolidation (months)Disease status at time/after of A2So3Treatment duration (weeks)OS since diagnosis (months)DeathOS since arsenic (months)Duration of response since As2O3 (months)Progression
ATL 6M51.6ChronicFAZT-IFN-VP1624.4SD/SD453Yes2822Yes
ATL 9M50.6ChronicFCHOP like20.1CR/CR648Yes2825Yes
ATL 11M27.7ChronicFLSG 15 + AZT-IFN13.2VGPR/CR697Yes8373Yesa
ATL 7F59.8AcuteFCHOP like6.2PD/PD48Yes1NAYes
ATL 14F35.1AcuteNFAlemtuzumab-CHOP2.2CR/CR412Yes105Yes
ATL 43F66.3LymphomaFCHOP like6.3CR/CR819Yes125Yes
ATL 44F54.8LymphomaFCHOP like3.8VGPR/CR836Yes3229Yes
ATL 64M63.1LymphomaNDCHOP/DHAOx13CR/CR865No5151No
ATL 65M54.4LymphomaNDCHOP4PR/PR1641Yes3610Yes
  1. M, male; F, female; CHOP, cyclcophosphamide, doxorubicine, oncovin, prednisone; DHAOx, dexamethasone, aracytine high dose, oxaliplatine; CR, complete response; PR, partial response; VGPR, very good partial response; SD, stable disease; PD, progressive disease
  2. F, functional; NF, non functional (this patient was found to have a p.V274A variant of TP53)
  3. aClone switch